CORRECTION: Guardant Health Q1 2024 Adj EPS $(0.46) Beats $(0.85) Estimate, Sales $168.500M Beat $150.673M Estimate
Portfolio Pulse from Benzinga Newsdesk
Guardant Health (NASDAQ:GH) reported Q1 2024 adjusted EPS of $(0.46), surpassing the $(0.85) estimate, with sales of $168.5M exceeding the $150.673M forecast. This represents a 30.91% increase in sales compared to the same period last year.

May 09, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health reported a significant beat on both EPS and sales estimates for Q1 2024, with a notable year-over-year sales growth.
Beating both EPS and sales estimates significantly, especially with a substantial year-over-year sales increase, is likely to be viewed positively by investors. This performance indicates not only that the company is growing but also that it is managing to exceed analyst expectations, which can lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100